The BioFuture™ 2024 conference, organized by Demy-Colton, concluded in New York and virtually, marking the largest turnout in the event’s history. This year’s conference brought together more than 100 speakers, over 100 investors, 62 presenting companies, and 48 journalists, all contributing to a dynamic exchange of ideas in life sciences, diagnostics, techbio, pharmaceuticals, health delivery, and digital health. The event featured a variety of public, private, and seed-stage innovation company presentations, 2,085 one-to-one meeting requests, 440 scheduled meetings, and media interviews, all focused on shaping the future of healthcare and related industries.
Key Highlights and Sessions
BioFuture 2024 showcased “Big Think” plenary sessions, fireside chats, and workshops that offered thought-provoking discussions on the major forces likely to transform healthcare in the coming decade. Topics spanned policy, artificial intelligence (AI), bioelectronics, the evolving funding landscape, and more. These sessions were designed to address critical issues facing healthcare leaders today, including the impact of emerging technologies on drug development, the role of AI in healthcare, and the financial and regulatory challenges impacting the sector.
Notable speakers included:
- Susan Hockfield, Ph.D., former President of MIT
- Kevin Tracey, M.D., President and CEO of Feinstein Institutes for Medical Research at Northwell Health
- Wade Davis, Vice President of Computational Science & Head of Digital for Research, Moderna
- Philippe Lopes-Fernandes, Executive Vice President and Chief Business Officer, Ipsen
- Seema Kumar, CEO of Cure
- Daniella Kranjac, Founding General Partner, Avant Bio
- Victoria Lipinska, Americas Lead for Quantum Innovation Centers, IBM
- Congressman Jake Auchincloss, MA-04
- Georgia Ravitz, Partner, FDA & Healthcare Regulatory at Orrick
- Nouhad Husseini, SVP of Business Development and Corporate Strategy at Regeneron Pharmaceuticals
- Members of the media including Max Bayer of Endpoints News, Hilary Brueck of Business Insider, Uduak Thomas of Genetic Engineering & Biotechnology News, and Sony Salzman of ABC News.
In coverage following the event, Scrip reporter Alaric DeArment highlighted the conference’s deep dive into critical topics in drug development, including the application of AI in improving efficiency and the challenges related to securing investment and navigating the cost of new therapies.
Ongoing Networking and Access
HelloPartnering, the platform used during BioFuture™, will remain open for six months (until April 30th), allowing participants to continue networking. While scheduling meetings will no longer be available, attendees can still reach out to each other. Registered participants can also access on-demand company presentations and session recordings through HelloPartnering, providing valuable insights and resources after the event.
Looking Ahead
Sara Jane Demy, Founder and CEO of Demy-Colton, reflected on the success of the event, stating, “Innovation thrives when visionary leaders and innovators come together. The growth of BioFuture this year is a testament to the value the conference provides in helping participants understand the market, policy, and other factors that impact the future of their businesses and healthcare. This year’s discussions addressed some of the most complex challenges in medicine and healthcare delivery—from the rise of techbio to the implementation of the Inflation Reduction Act. Our industry is at a critical turning point, and we look forward to continuing these forward-thinking conversations at Biotech Showcase in January.”
Biotech Showcase
Biotech Showcase is another key event organized by Demy-Colton, bringing together private biotechnology companies, investors, and media. This premier investor conference will feature more than 3,400 attendees, including nearly 1,300 investors and 110 media representatives. The event provides a platform for private biotechnology companies to present their innovations to investors and the media, helping drive the future of the biotech industry.
About BioFuture
Sponsored by Aisling Capital, Pappas Capital, Regeneron, JP Morgan, BioWorld, Emerald Bioventures, KKH Advisors, BKW, Cure, ENTENTE Network of Companies/ENMEDIA, EntityRisk, IPSEN, Mineralys, NYC Economic Development Corporation, Orrick, and Wilson Sonsini, BioFuture is the premier conference where therapeutic pioneers, innovators, and investors converge to shape the future of healthcare, digital health, and life sciences.
About Demy-Colton
Demy-Colton is a leading organization specializing in life sciences events, dedicated to connecting industry leaders and fostering partnerships that drive global life sciences innovation. Its portfolio includes prominent events such as Biotech Showcase™, BioFuture™, and the Biotech CEO Summits held in Europe and La Jolla, as well as virtual events designed to maintain year-round engagement within the life sciences community.
